People
-
Verona Pharma has announced a clinical development services agreement with QuintilesIMS for Verona’s RPL554, an inhaled PDE3/PDE4 inhibitor for the treatment of acute exacerbations in COPD patients. The company also said that it is planning… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) has announced that Lars Asking, who has served as VP of MVIC since May 2016, will become CEO of the consortium as of May 2017. Asking will take over… Read more . . .
-
Milestone Pharmaceuticals has announced the appointment of Joseph G. Oliveto as President and CEO. Oliveto, who was most recently CEO of Galleon Pharmaceuticals and previously served as President and CEO of Chelsea Therapeutics, is replacing… Read more . . .
-
Intranasal drug developer Impel NeuroPharma has announced the appointment of former MAP Pharmaceuticals President and CEO Timothy S. Nelson as Independent Director of the Board of Directors. Nelson led MAP Pharmaceuticals when it was acquired… Read more . . .
-
Lovelace Biomedical, a not-for-profit research organization which offers inhalation toxicology and other services for inhaled drug development, has announced the appointment of Larry Mallis as Director of Bioanalytical Operations. Mallis was most recently Director of… Read more . . .
-
OptiNose has announced that Keith A. Goldan has joined the company as Chief Financial Officer. Goldan was most recently Senior VP and CFO of Fibrocell and previously served as CFO at NuPathe, PuriCore (now Realm… Read more . . .
-
Smartinhaler maker Adherium has announced the appointment of former MicroDose Therapeutx co-founder Scott Fleming as Senior VP of Business Development, Europe, effective immediately. Fleming replaces John Tarplee who left the company at the end of… Read more . . .
-
OINDP development specialist Nanopharm has appointed Arron Danson as Head of Device Development, the company said. Danson has extensive experience in the development of pulmonary and nasal delivery devices, having worked at companies such as… Read more . . .
-
Avanir Pharmaceuticals, which launched its Onzetra Xsail intranasal dry powder sumatriptan in the US in May 2016, has announced the appointment of Richard Malamut as Senior VP, Research and Development and Chief Medical Officer. Malamut… Read more . . .
-
Inhaled drug developer Savara Pharmaceuticals has announced the appointment of former Edgemont Pharmaceuticals CFO David L. Lowrance as its new Chief Financial Officer. Savara cited Lowrance’s experience leading IPOs for Acucela, where he was CFO… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden